ArticleFrontiers in oncology2021
Integration of scRNA-Seq and Bulk RNA-Seq to Analyse the Heterogeneity of Ovarian Cancer Immune Cells and Establish a Molecular Risk Model.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed.
- Analysis and validation of prognostic markers for thyroid cancer by single-cell and bulk RNA sequencing.Translational cancer research · 2026Article
- Single-cell immune subtyping of basophils in head and neck squamous cell carcinoma and a prognostic model based on bulk RNA sequencing.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Identification of colorectal cancer molecular subtypes and prognostic features based on basement membrane-related genes.Journal of applied genetics · 2026Article
- Mitochondrial metabolism-associated biomarkers in oral lichen planus and oral squamous cell carcinoma.Functional & integrative genomics · 2026Article
- An Exploratory In Silico Analysis ofCancers · 2026Article
- Deciphering IFN signaling in gastric cancer: A single-cell and bulk transcriptomic integration reveals CXCR4 as a key immunomodulator and prognostic determinant.Translational oncology · 2026Article
- Spatial habitats radiomics from multiparametric magnetic resonance imaging predict platinum resistance in epithelial ovarian cancer.Journal of ovarian research · 2026Article
- Molecular and cellular landscapes of the immune microenvironment and multiomic biomarker-sets in platinum-resistant recurrent ovarian cancers.Journal of ovarian research · 2026Review
- Spatiotemporal transcriptomic insights into ferroptosis and TFRC-linked immune interactions in ischemia-reperfusion acute kidney injury.Genes and immunity · 2026Article
- Integrated single-cell and transcriptomic analysis of CD8Translational cancer research · 2026Article
- Multi-Scale Transcriptomics Redefining the Tumor Immune Microenvironment.Biotech (Basel (Switzerland)) · 2026Review
- Discovery of Anoikis-correlated Biomarkers for Ovarian Cancer Through Integrated Transcriptome and Single-cell RNA Sequencing Analyses.Current topics in medicinal chemistry · 2026Article
- PANoptosis-based HNSCPAN-index predicts prognosis and reveals DSCAM as a therapeutic target in head and neck squamous cell carcinoma.PloS one · 2026Article
- Mendelian Randomization and Single-Cell RNA Sequencing Reveal CKAP4 and PFDN5 as Tumor Cell-Specific Causal Genes for Glioblastoma.International journal of general medicine · 2026Article
- Transcriptomics-based analysis of muscle injury mechanism mediated by inflammatory imbalance in the Duchenne muscular dystrophy muscle microenvironment.Frontiers in neurology · 2026Article
- Identification of Notch pathway-related biomarkers in patients with idiopathic pulmonary fibrosis.PloS one · 2026Article
- Novel role of NR1D1 and SLC7A5 in gestational diabetes mellitus: regulation of polyamine metabolism.Journal of diabetes and metabolic disorders · 2025Article
- RNA sequencing in ovarian cancer research: a comprehensive review.Journal of ovarian research · 2025Review
- scRNA-seq Can Identify Different Cell Populations in Ovarian Cancer Bulk RNA-seq Experiments.International journal of molecular sciences · 2025Article
- Prognostic value of circadian rhythm-associated genes in breast cancer.World journal of surgical oncology · 2025Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConsiderable evidence suggests that the heterogeneity of ovarian cancer (OC) is a major cause of treatment failure. Single-cell RNA sequencing (scRNA-seq) is a powerful tool to analyse the heterogeneity of the tumour at the single-cell level, leading to a better understanding of cell function at the genetic and cellular levels.
methodsOC scRNA-seq data were extracted from the Gene Expression Omnibus (GEO) database and the FindCluster () package used for cell cluster analysis. The GSVA package was used for single-sample gene set enrichment analysis (ssGSEA) analysis to obtain a Hallmark gene set score and bulk RNA-seq data were used to analyse the key genes of OC-associated immune cell subsets. CIBERSORT was used to identify immune scores of cells and the "WGCNA" package for the weighted correlation network analysis (WGCNA). KEGG (Kyoto Encyclopedia of Genes and Genomes) and GO (Gene Ontology) analyses of subtype groups were performed by GSEA. Then, univariate Cox and lasso regression were performed to further establish a signature. Finally, qPCR and immunohistochemistry staining were used to evaluate the expression of signature genes in OC.
resultsTwo scRNA-seq (GSE154600 and GES158937) datasets were integrated to obtain 20 cell clusters. T cells or NK cells (cluster 5, 6, 7, 11), B cells (cluster 16, 19, 20) and myeloid cells (cluster 4, 9, 10) were clustered according to immune cell markers. The ssGSEA revealed that M1- and M2-like myeloid cell-related genes were significantly upregulated in P3 and P4 patients in the GSE154600 data. Immune cell analysis in TCGA-OC showed that a high abundance of M1-like tumour-associated macrophages (TAMS) predicts better survival. WGCNA, univariate Cox and lasso Cox regression established a two-gene signature (RiskScore=-0.059*CXCL13-0.034*IL26). Next, the TCGA-test and TCGA-OC were used to test the risk prediction ability of the signature, showing a good effect in the datasets. Moreover, the qPCR and immunohistochemistry staining revealed that the expression of CXCL13 and IL26 was reduced in OC tissues.
conclusionA two-gene signature prognostic stratification system (CXCL13 and IL26) was developed based on the heterogeneity of OC immune cells to accurately evaluate the prognostic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.